Judith Klimkait

Judith Klimkait leads iPSC-derived cell therapy development at Century Therapeutics, working on engineering iPSC lines with multiple genetic modifications to create off-the-shelf T cell and NK cell products with enhanced anti-tumor activity and immune evasion capabilities. Her team has developed protocols for efficient differentiation of gene-edited iPSC lines into functional T cells that maintain CAR expression and cytotoxic function. She is advancing multiplexed gene editing approaches to create universal donor iPSC master cell banks.